Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Does Evolocumab Lower Lipoprotein Particles?

Am J Cardiol; ePub 2017 Nov 8; Toth, et al

Evolocumab significantly lowers atherogenic lipoprotein particles (LDL-P), including low-density and remnant lipoproteins, a recent study found. The post-hoc sub-analysis included 619 patients from the DECARTES trial, a 52-week, randomized, double-blind, placebo-controlled, global study of patients with hyperlipidemia. At baseline, mean LDL-P concentration was 1,077 nmol/L for the placebo group and 1,100 nmol/L for the evolocumab group. Researchers found:

  • In patients receiving evolocumab, week 52 total LDL-P concentration decreased to 610 nmol/L, a treatment difference of 50% vs placebo.
  • Evolocumab also reduced concentrations of medium VLDL-P, small VLDP-P, and IDL-P.
  • Mean changes in total LDL particle size in the evolocumab group was ‒1.7.
  • Changes in total LDL, HDL, and VLDL particle sizes were all significant vs placebo.

Citation:

Toth PP, Sattar N, Blom DJ, et al. Effect of evolocumab on lipoprotein particles. [Published online ahead of print November 8, 2017]. Am J Cardiol. doi:10.1016/j.amjcard.2017.10.028.

This Week's Must Reads

Lipid Testing After Acute Myocardial Infarction, J Am Heart Assoc; ePub 2018 Jan 25; Wang, et al

Clinical Pharmadynamics of Evolocumab, Clin Pharmacokinet; ePub 2018 Jan 20; Kasichayanula, et al

Lipoproteins & CV Outcomes in Dialysis Patients, J Clin Lipidol; ePub 2017 Dec 26; Kaysen, et al

Is Dual Lipid-Lowering Therapy Better?, Atherosclerosis; 2018 Feb; Gragnano, et al

sLOX-1 in Ischemic Stroke & Transient Ischemic Attack, J Am Heart Assoc; ePub 2018 Jan 12; Skarpengland, et al

Must Reads in Hypercholesterolemia

Lipid Testing After Acute Myocardial Infarction, J Am Heart Assoc; ePub 2018 Jan 25; Wang, et al

Clinical Pharmadynamics of Evolocumab, Clin Pharmacokinet; ePub 2018 Jan 20; Kasichayanula, et al

Lipoproteins & CV Outcomes in Dialysis Patients, J Clin Lipidol; ePub 2017 Dec 26; Kaysen, et al

Is Dual Lipid-Lowering Therapy Better?, Atherosclerosis; 2018 Feb; Gragnano, et al

sLOX-1 in Ischemic Stroke & Transient Ischemic Attack, J Am Heart Assoc; ePub 2018 Jan 12; Skarpengland, et al